View Author
patient hepatitis treatment response therapy study liver interferon hepatitis b genotype hepatitis c group virus disease hbeag ribavirin lamivudine level cirrhosis infection combination hepatology hepatitis b virus score analysis model table result signi baseline fi brosis peptide hepatitis c virus effect hbsag virological trial month serum stage liver patients peg-ifn gastroenterology signi ficantly brosi hbv dna outcome hrqol number population control combination therapy liver disease virological response reduction t-cell seroconversion netherland health hcv-rna assay sequence hbeag seroconversion university hepatocellular carcinoma dose reduction relapse monotherapy peginterferon rotterdam value hbv dna levels mutation difference kinetic hepatocellular hospital diabetes mellitus plasma cirrhotic
10 Most Recent Publications
|
Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: A systematic review
(Article)
Toy, M. Önder, F.O. Wörmann, T. Bozdayi, A.M. Schalm, S.W. Borsboom, G.J. Rosmalen, J.M. van Richardus, J.H. Yurdaydin, C. |
2011-12-12
|
|
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
(Article)
Bochud, P.-Y. Bibert, S. Hellstrand, K. Neumann, A.U. Lagging, M. Negro, F. Haagmans, B.L. Soulier, A. Ferrari, C. Missale, G. Zeuzem, S. Pawlotsky, J.M. Schalm, S.W. |
2011-11-01
|
|
Prediction of nonSVR to therapy with pegylated interferon-α2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment
(Article)
Lukasiewicz, E. Gorfine, M. Freedman, L.S. Pawlotsky, J.M. Schalm, S.W. Ferrari, C. Zeuzem, S. Neumann, A.U. |
2010-05-01
|
|
Screening and Early Treatment of Migrants for Chronic Hepatitis B Virus Infection Is Cost-Effective
(Article)
Veldhuizen, I.K. Toy, M. Hahné, S.J. Wit, G.A. de Schalm, S.W. Man, R.A. de Richardus, J.H. |
2010-02-01
|
|
Clinical use of interferon in hepatitis B and C.
(Article)
Schalm, S.W. |
2009-01-01
|
|
High impact of migration on the prevalence of chronic hepatitis B in the Netherlands
(Article)
Marschall, T. Kretzschmar, M. Mangen, M-.J.J. Schalm, S.W. |
2008-12-01
|
|
Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues
(Article)
Buster, E.H.C.J. Schalm, S.W. Janssen, H.L.A. |
2008-12-01
|
|
Preface
(Article)
Janssen, H.L.A. Schalm, S.W. |
2008-12-01
|
|
Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-α2a/ribavirin therapy
(Article)
Pugnale, P. Herrmann, E. Neumann, A.U. Pawlotsky, J.M. Schalm, S.W. Ferrari, C. Homburger, Y. Zeuzem, S. Negro, F. |
2008-06-01
|
|
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus
(Article)
Veldt, B.J. Chen, W. Schalm, S.W. Janssen, H.L.A. Heathcote, E.J. Wedemeyer, H. Reichen, J. Hofmann, W.P. Knegt, R.J. de Zeuzem, S. Manns, M.P. Hansen, B.E. |
2008-06-01
|
